Community Epidemiology and Typology of Third-generation Cephalosporins Resistant Enterobacteriaceae in Reunion Island

Bacterial Resistance Clinical Trial

— AB-RUN  

Official title:

Community Epidemiology and Typology of Third-generation Cephalosporins Resistant Enterobacteriaceae (Prevalence, Resistance Mechanisms and Risk Factors) in Reunion Island

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03226314
• Other study ID #: 2015/CHU/14
• Status: Active, not recruiting
• Start date: November 21, 2017
• Est. completion date: June 30, 2019

Study information

• Verified date: March 2019
• Source: Centre Hospitalier Universitaire de la Réunion
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In its report dated april 2014, World Health Organization confirms antibiotic resistance dissemination in all parts of the world, in hospitals and in community and worries about a possible comeback to a pre-antibiotic era during the 21st century. For the last 15 years, third-generation cephalosporins resistant enterobacteriaceae (3GCREB) prevalence is continuously increasing. Community 3GCREB prevalence has not been studied whereas several observations made in Reunion Island hospital suggest a diffusion in community. In this situation of world-wide and regional extension of bacterial resistance, the investigator offers to study bacterial resistance to antibiotic in Reunion Island community.

Description:

The investigator is focused on E. coli species exhibiting BLSE or metallo-betalactamases production that could be encountered du to the increasing level of migratory flow in Reunion Island.

Fecal sample collection will be used for further investigations on bacterial typology.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 500
• Est. completion date: June 30, 2019
• Est. primary completion date: December 1, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients:

• aged over 18 years old

• admitted in emergency ward or intensive care of the university hospital of Reunion Island

• who received the patient information notice and who gave their consent

• who have a stool sample performed in the 48 hours following admission

• who understand and can read French

Exclusion Criteria:

Patients:

• transferred from a short-term, middle-term or long-term stay health facility

• who have a stool sample performed more than 48 hours following admission.

Related Conditions & MeSH terms

• Bacterial Resistance

Intervention

Procedure:
• stool sample
study will be proposed to all patients entering emergency ward or intensive care unit in Reunion Island university hospital. Upon consent, a stool sample will be taken (either directly on emitted stools or by rectal sampling) and analysed for enterobacteriaceae.

Locations

Country	Name	City	State
Réunion	Chu Reunion Island	Saint-Pierre	Reunion Island

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de la Réunion

Country where clinical trial is conducted

Réunion, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Digestive prevalence rate of 3GCREB	estimate of digestive prevalence rate of 3GCREB in participating patients and extrapolation to Reunion Island community population.	through study completion, an average of 1 day